Our top pick for
Zimmer Biomet Holdings, Inc is a medical devices business based in the US. Zimmer Biomet shares (ZBH) are listed on the NYSE and all prices are listed in US Dollars. Zimmer Biomet employs 20,000 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$108.02 - $179.19|
|50-day moving average||$163.01|
|200-day moving average||$154.18|
|Wall St. target price||$181.73|
|Dividend yield||$0.96 (0.54%)|
|Earnings per share (TTM)||$0.18|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Zimmer Biomet stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Zimmer Biomet's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Zimmer Biomet's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 815x. In other words, Zimmer Biomet shares trade at around 815x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Zimmer Biomet's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.9748. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Zimmer Biomet's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Zimmer Biomet's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2 billion.
The EBITDA is a measure of a Zimmer Biomet's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$7 billion|
|Operating margin TTM||13.25%|
|Gross profit TTM||$4.9 billion|
|Return on assets TTM||2.37%|
|Return on equity TTM||-1.12%|
|Market capitalisation||$36.8 billion|
TTM: trailing 12 months
There are currently 2.6 million Zimmer Biomet shares held short by investors – that's known as Zimmer Biomet's "short interest". This figure is 3.4% up from 2.5 million last month.
There are a few different ways that this level of interest in shorting Zimmer Biomet shares can be evaluated.
Zimmer Biomet's "short interest ratio" (SIR) is the quantity of Zimmer Biomet shares currently shorted divided by the average quantity of Zimmer Biomet shares traded daily (recently around 1.2 million). Zimmer Biomet's SIR currently stands at 2.13. In other words for every 100,000 Zimmer Biomet shares traded daily on the market, roughly 2130 shares are currently held short.
However Zimmer Biomet's short interest can also be evaluated against the total number of Zimmer Biomet shares, or, against the total number of tradable Zimmer Biomet shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Zimmer Biomet's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Zimmer Biomet shares in existence, roughly 10 shares are currently held short) or 0.0125% of the tradable shares (for every 100,000 tradable Zimmer Biomet shares, roughly 13 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Zimmer Biomet.
Find out more about how you can short Zimmer Biomet stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Zimmer Biomet.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 40.16
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Zimmer Biomet's overall score of 40.16 (as at 12/31/2018) is pretty weak – landing it in it in the 77th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Zimmer Biomet is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 9.29/100
Zimmer Biomet's environmental score of 9.29 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Zimmer Biomet is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 23.4/100
Zimmer Biomet's social score of 23.4 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Zimmer Biomet is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 16.46/100
Zimmer Biomet's governance score puts it squarely in the 9th percentile of companies rated in the same sector. That could suggest that Zimmer Biomet is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Zimmer Biomet scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Zimmer Biomet has, for the most part, managed to keep its nose clean.
|Total ESG score||40.16|
|Total ESG percentile||77.24|
|Environmental score percentile||9|
|Social score percentile||9|
|Governance score percentile||9|
|Level of controversy||2|
Dividend payout ratio: 16.93% of net profits
Recently Zimmer Biomet has paid out, on average, around 16.93% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.54% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Zimmer Biomet shareholders could enjoy a 0.54% return on their shares, in the form of dividend payments. In Zimmer Biomet's case, that would currently equate to about $0.96 per share.
While Zimmer Biomet's payout ratio might seem low, this can signify that Zimmer Biomet is investing more in its future growth.
Zimmer Biomet's most recent dividend payout was on 29 April 2021. The latest dividend was paid out to all shareholders who bought their shares by 25 March 2021 (the "ex-dividend date").
Over the last 12 months, Zimmer Biomet's shares have ranged in value from as little as $108.0234 up to $179.19. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Zimmer Biomet's is 1.3304. This would suggest that Zimmer Biomet's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Zimmer Biomet Holdings, Inc. , together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S. E. T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as surgical, bone cement, and office-based technology products.
Everything we know about the Krispy Kreme IPO, plus information on how to buy in.
Everything we know about the Day One Biopharmaceuticals IPO, plus information on how to buy in.
Everything we know about the Enact Holdings IPO, plus information on how to buy in.
Everything we know about the Solid Power IPO, plus information on how to buy in.
Everything we know about the Paymentus Holdings IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Ximalaya IPO, plus information on how to buy in.
Everything we know about the Zeta Global Holdings Corp IPO, plus information on how to buy in.
Everything we know about the Paycor HCM IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.